Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Biparatopic nanobodies protect mice from lethal challenge with SARS‐CoV‐2 variants of concern
Teresa R. Wagner, Daniel Schnepf, Julius Beer, et al.
EMBO Reports (2021) Vol. 23, Iss. 2
Open Access | Times Cited: 25

Showing 25 citing articles:

Nanobodies: Robust miniprotein binders in biomedicine
Jeffrey Yong Joon Kim, Zhe Sang, Yufei Xiang, et al.
Advanced Drug Delivery Reviews (2023) Vol. 195, pp. 114726-114726
Open Access | Times Cited: 44
Biparatopic antibodies: therapeutic applications and prospects
David L. Niquille, Kyle M. Fitzgerald, Nimish Gera
mAbs (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 24
Mind the “Vaccine Fatigue”
Zhaohui Su, Ali Cheshmehzangi, Dean McDonnell, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 63
Impaired immune response drives age-dependent severity of COVID-19
Julius Beer, Stefania Crotta, Angele Breithaupt, et al.
The Journal of Experimental Medicine (2022) Vol. 219, Iss. 12
Open Access | Times Cited: 42
Therapeutic nanobodies against SARS-CoV-2 and other pathogenic human coronaviruses
Yang Yang, Fang Li, Lanying Du
Journal of Nanobiotechnology (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 9
Nanoscale warriors against viral invaders: a comprehensive review of Nanobodies as potential antiviral therapeutics
Vaishali Verma, N. D. Sinha, A. Raja
mAbs (2025) Vol. 17, Iss. 1
Open Access | Times Cited: 1
The Potential of Nanobodies for COVID-19 Diagnostics and Therapeutics
Dhaneshree Bestinee Naidoo, Anil A. Chuturgoon
Molecular Diagnosis & Therapy (2023) Vol. 27, Iss. 2, pp. 193-226
Open Access | Times Cited: 20
A potent alpaca-derived nanobody that neutralizes SARS-CoV-2 variants
Jules B. Weinstein, Timothy A. Bates, Hans C. Leier, et al.
iScience (2022) Vol. 25, Iss. 3, pp. 103960-103960
Open Access | Times Cited: 27
Mechanism-Driven Design of Multispecific Antibodies for Targeted Disease Treatment
Justyn Fine, Bunyarit Meksiriporn, Jiacheng Tan, et al.
Annual Review of Chemical and Biomolecular Engineering (2024) Vol. 15, Iss. 1, pp. 105-138
Closed Access | Times Cited: 5
Generation and characterization of antagonistic anti-human CD39 nanobodies
Stephan Menzel, Yinghui Duan, Julia Hambach, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 5
Extracellular modulation of TREK-2 activity with nanobodies provides insight into the mechanisms of K2P channel regulation
Karin E. J. Rödström, Alexander Cloake, Janina Sörmann, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 5
COVID-19 patient serum less potently inhibits ACE2-RBD binding for various SARS-CoV-2 RBD mutants
Daniel Junker, Alex Dulovic, Matthias Becker, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 21
Emerging Landscape of Nanobodies and Their Neutralizing Applications against SARS-CoV-2 Virus
Xuemei Feng, Hu Wang
ACS Pharmacology & Translational Science (2023) Vol. 6, Iss. 7, pp. 925-942
Open Access | Times Cited: 11
Two birds with one stone: human SIRPα nanobodies for functional modulation and in vivo imaging of myeloid cells
Teresa R. Wagner, Simone Blaess, Inga B. Leske, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 9
Structural and functional characterization of nanobodies that neutralize Omicron variants of SARS-CoV-2
Katy Cornish, Jiandong Huo, Luke Jones, et al.
Open Biology (2024) Vol. 14, Iss. 6
Open Access | Times Cited: 3
Inhibition of cGAS ameliorates acute lung injury triggered by zinc oxide nanoparticles
Ziqi Jiang, Yu Jiang, Jingchuan Fan, et al.
Toxicology Letters (2022) Vol. 373, pp. 62-75
Closed Access | Times Cited: 14
A Naïve Phage Display Library-Derived Nanobody Neutralizes SARS-CoV-2 and Three Variants of Concern
Dandan Wu, Junxiao Cong, Jiali Wei, et al.
International Journal of Nanomedicine (2023) Vol. Volume 18, pp. 5781-5795
Open Access | Times Cited: 4
Extracellular modulation of TREK-2 activity with nanobodies provides insight into the mechanisms of K2P channel regulation
Karin E. J. Rödström, Alexander Cloake, Janina Sörmann, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 3
Therapeutic Phage Display-Derived Single-Domain Antibodies for Pandemic Preparedness
Janet M. Daly, Theam Soon Lim, Kevin C. Gough
Antibodies (2023) Vol. 12, Iss. 1, pp. 7-7
Open Access | Times Cited: 2
Bispecific antibodies and its applications: a novel approach for targeting SARS-Cov-2
Ajay Kumar Shukla, Saurav Misra
Journal of Basic and Clinical Physiology and Pharmacology (2023) Vol. 34, Iss. 2, pp. 161-168
Closed Access | Times Cited: 1
Impaired immune response drives age-dependent severity of COVID-19
Julius Beer, Stefania Crotta, Angele Breithaupt, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 2
Two birds with one stone: human SIRPα nanobodies for functional modulation and in vivo imaging of myeloid cells
Teresa R. Wagner, Simone Blaess, Inga B. Leske, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
Production of nanobodies in Andean camelids and their most common applications: A general review in the medical field.
Cilleruelo Ortega, L M Rivera, Luis E Trujillo
Bionatura (2023) Vol. 8, Iss. 2, pp. 1-12
Open Access
A potent alpaca-derived nanobody that neutralizes SARS-CoV-2 variants
Jules B. Weinstein, Timothy A. Bates, Hans C. Leier, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access
Page 1

Scroll to top